Supplementary Figure S4. Oncolytic adenoviruses inhibit tumor growth, while trastuzumab transgene does not add to efficacy against HER2-negative breast cancer in vivo from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

3-4 week-old female nude/NMRI mice (Harlan Laboratories) were xenografted in both flanks with MDA-MB-436 triple-negative breast cancer cells (6Ã-106 cells/tumor). When tumors reached 5 mm in diameter, mice were randomized and treated intratumorally with 2Ã-109 VP of Ad5/3-Î"24 or Ad5/3-Î"24-tras, or mock-treated (PBS only) on indicated days, and tumor growth was monitored. Trastuzumab-coding Ad5/3-â^†24-tras virus treatment resulted in significant tumor-growth inhibition as compared mock (P